East London Foundation Trust Foundation (ELFT):
New Medicines Review

NAME OF DRUG
LAUNCHED BY
APPROVED

Content of review

1. Summary

BRIEF OVERVIEW OF ALL THE SECTIONS ABOVE.

SHOULD BE ONLY A FEW PARAGRAPHS

2. Product Overview (1)

Background
of synaptic noradrenaline transmission at the apha2 adrenergic receptors. (1-3).

Licenced indication

Dose schedule

Interactions

Monitoring

3. Clinical Efficacy

POPULATION SAMPLE
LICENSED INDICATION
CLINICAL/ RESEARCH EVIDENCE

SHOULD BE ABOUT TWO PARAGRAPHS SPECIFICALLY TALKING ABOUT EFFICACY.

4. Evidence Synopsis

Author	Summary	Primary outcome	Secondary outcome	Main findings	Limitations/ Side effects

5. Safety

ADVERSE EFFECTS> MOST COMMON TO MORE SERIOUS
EVIDENCE BASE TO SUPPORT E.G. SPC, RESEARCH, OTHER REVIEWS

A FEW PARAGRAPHS

6. Alternative pharmacological interventions

Licensed options:
Off label/ unlicensed treatments:

7. Budget impact

COST INFORMATION FROM E.G. NHS EVIDENCE SUMMARY, DRUG TARIFF

PRICES FOR DIFFERENT PACK SIZES

PROJECTED COST> 28 DAY AND ANNUAL

COST COMPARISON IF APPROPRIATE TO EQUIVALENT PRODUCTS

COST PROJECTION FOR THE DRUG AND/ OR IN COMPARISON TO EQUIVALENT PRODUCTS

Estimated cost projection for ELFT

COST FROM ELFT

8. Funding

Cost of initiation and maintenance
CCG
Transfer of care and cost would need to be agreed with CCG and GPs

9. Recommendations

SUMMARISE IN A FEW BULLETINS

10. Decision from Medicine Management Committee

- TO BE ADDED AFTER MEDS COMM
- SUMMARISE IN A FEW BULLET POINTS

References

USE NUMBER REFERENCE SYSTEM AND USE APPROPRIATE NUMBER IN THE BODY OF THE TEXT.
REFERENCE TO BE ADDED IN BRACKETS AT THE END OF THE SENTENCE/ PARAGRAPH OR SUPERSCRIPT.
EXAMPLES OF REFERENCES WRITING BELOW:

1. Intuniv® 1mg, 2mg, 3mg, 4mg prolonged-release tablets. Summary of Product Characteristics (SPC), Shire Pharmaceuticals. http://www.medicines.org.uk
2. Attention deficit hyperactivity disorder in children and young people: guanfacine prolonged-release; NICE Evidence summary: new medicine; Published 22 March 2016. https://www.nice.org.uk/advice/esnm70/chapter/Key-points-from-the-evidence
3. Guanfacine, 1mg,2mg,3mg and 4mg prolonged-release tablets (Intuniv®), Scottish Medicines Consortium, SMC No.1123/16. https://www.scottishmedicines.org.uk/About_SMC/Latest_news/News_Articles/February_2016_decisions_news_release
4. Summary of the risk management plan (RMP) for Intuniv (guanfacine).European Medicines Agency, EMA/530486/2015. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003759/WC500195132.pdf
5. Hervas A, Huss M, Johnson M et al. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: A randomized, controlled, Phase III trial. Eur.Neuropsychopharmacology. 2014; 24:1861-1872.

Complied by	**NAME OF PERSON WHO WROTE REVIEW**	**DATE**
Reviewed by	**BODIES E.G. MEDS COMM**	**DATE**